Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 884,004 shares, a decline of 51.7% from the October 15th total of 1,830,062 shares. Based on an average daily trading volume, of 451,248 shares, the short-interest ratio is presently 2.0 days. Approximately 2.8% of the shares of the company are sold short.

A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Northern Trust Corp increased its position in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 61.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 77,213 shares of the company’s stock after buying an additional 29,354 shares during the period. Northern Trust Corp owned about 0.24% of Rexahn Pharmaceuticals worth $117,000 at the end of the most recent quarter.

NYSEAMERICAN:RNN opened at $1.17 on Friday. Rexahn Pharmaceuticals has a one year low of $1.03 and a one year high of $2.70.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its quarterly earnings data on Monday, November 5th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17).

Several equities research analysts have recently commented on the company. Ifs Securities upgraded Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, October 4th. B. Riley set a $8.00 price objective on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. HC Wainwright set a $20.00 price objective on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Finally, Zacks Investment Research lowered Rexahn Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 16th.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Recommended Story: How is an ETF different from a mutual fund?

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.